Page last updated: 2024-08-21

quinazolines and azd3759

quinazolines has been researched along with azd3759 in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (71.43)24.3611
2020's4 (28.57)2.80

Authors

AuthorsStudies
Chen, K; Cheng, Z; Johnström, P; Li, DY; Varnäs, K; Wang, J; Yang, ZF; Zeng, Q; Zhang, X1
Afzelius, L; Ahlgren, C; Farde, L; Gruber, S; Halldin, C; Jerning, E; Johnström, P; Juréus, A; Malmborg, J; Schött, P; Schou, M; Varnäs, K1
Ahn, MJ; Bai, Y; Chen, K; Cheng, Z; Guo, Q; Kim, DW; Rabbie, S; Wang, Y; Xu, Y; Yang, JC; Yang, Z; Yin, X; Zhang, L; Zhang, X1
Deng, Z; Mu, Y; Sun, P; Xiong, S; Xue, M; Zhou, R1
Planchard, D1
Ahn, JS; Ahn, MJ; Cho, BC; Goldman, JW; Harrop, B; John, T; Kao, S; Kim, DW; Kim, HR; Kim, SW; Kim, TM; Lee, JS; Lin, CC; Natale, R; Overend, P; Rabbie, S; Su, WC; Yang, JC; Yang, Z1
Li, X; Wang, J; Wang, Y; Xing, L; Yang, Z; Yu, J; Zhang, T; Zheng, L1
Aarons, L; Martin, EC; Yates, JWT1
Chao, D; Liu, K; Pang, L; Shi, Y; Wang, W1
Chen, K; Colclough, N; Fridén, M; Johnström, P; McGinnity, DF1
Cai, E; Del Cid Pellitero, E; Durcan, TM; Fon, EA; Larroquette, F; Luo, W; Soubannier, V; Tavassoly, O; Thomas, RA1
Deng, Q; Ma, S; Mao, Y; Yin, W; Yu, Q; Zhang, K; Zhao, R2
Liang, Y; Meng, F; Qiao, Z; Zhi, S1

Trials

1 trial(s) available for quinazolines and azd3759

ArticleYear
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
    The Lancet. Respiratory medicine, 2017, Volume: 5, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Piperazines; Quinazolines; Republic of Korea; Taiwan; Treatment Outcome; United States

2017

Other Studies

13 other study(ies) available for quinazolines and azd3759

ArticleYear
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
    Journal of medicinal chemistry, 2015, Oct-22, Volume: 58, Issue:20

    Topics: Animals; Brain; Brain Neoplasms; Central Nervous System; Clinical Trials, Phase I as Topic; Dogs; Drug Discovery; ErbB Receptors; Macaca fascicularis; Male; Mice; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Rats, Wistar; Xenograft Model Antitumor Assays

2015
Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676.
    The Journal of pharmacology and experimental therapeutics, 2016, Volume: 358, Issue:3

    Topics: Animals; Benzofurans; Blood Proteins; Brain; Humans; Macaca fascicularis; Memory; Mice; Piperazines; Positron-Emission Tomography; Psychotropic Drugs; Quinazolines; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Serotonin 5-HT1 Receptor Antagonists

2016
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.
    Science translational medicine, 2016, 12-07, Volume: 8, Issue:368

    Topics: Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Central Nervous System Neoplasms; Disease Models, Animal; ErbB Receptors; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Quinazolines; Spinal Cord

2016
Determination of AZD3759 in rat plasma and brain tissue by LC-MS/MS and its application in pharmacokinetic and brain distribution studies.
    Journal of pharmaceutical and biomedical analysis, 2017, Jun-05, Volume: 140

    Topics: Animals; Brain; Chromatography, Liquid; Piperazines; Quinazolines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry

2017
AZD3759 for CNS metastases in EGFR-mutant lung cancer.
    The Lancet. Respiratory medicine, 2017, Volume: 5, Issue:11

    Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines

2017
Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer.
    International journal of cancer, 2018, 07-01, Volume: 143, Issue:1

    Topics: Animals; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; DNA Repair; ErbB Receptors; Female; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Mice; Mutation; Piperazines; Quinazolines; Radiation-Sensitizing Agents; Xenograft Model Antitumor Assays

2018
Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse models.
    Cancer chemotherapy and pharmacology, 2018, Volume: 82, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Luminescent Measurements; Lung Neoplasms; Mice; Neoplasm Staging; Piperazines; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays

2018
AZD3759 induces apoptosis in hepatoma cells by activating a p53-SMAD4 positive feedback loop.
    Biochemical and biophysical research communications, 2019, 02-05, Volume: 509, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Piperazines; Quinazolines; Signal Transduction; Smad4 Protein; Tumor Suppressor Protein p53

2019
Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery.
    Drug discovery today, 2019, Volume: 24, Issue:5

    Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Drug Discovery; Humans; Piperazines; Protein Kinase Inhibitors; Quinazolines

2019
Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates α-synuclein Pathology in a Mouse Model of α-Synuclein Propagation.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021, Volume: 18, Issue:2

    Topics: alpha-Synuclein; Animals; Blood-Brain Barrier; Brain; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Male; Mice; Mice, Inbred C57BL; Piperazines; Quinazolines; RNA, Small Interfering; Synucleinopathies

2021
AZD3759 inhibits glioma through the blockade of the epidermal growth factor receptor and Janus kinase pathways.
    Bioengineered, 2021, Volume: 12, Issue:1

    Topics: Animals; Apoptosis; Brain Neoplasms; Cell Proliferation; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioma; Humans; Janus Kinases; Male; Mice; Piperazines; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2021
AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1.
    Bioengineered, 2022, Volume: 13, Issue:1

    Topics: Acrylamides; Aniline Compounds; Animals; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 1; Lung Neoplasms; Mice; Mice, Nude; Piperazines; Quinazolines; Xenograft Model Antitumor Assays

2022
Molecular dynamics simulations of a central nervous system-penetrant drug AZD3759 with lipid bilayer.
    Journal of molecular modeling, 2022, Aug-19, Volume: 28, Issue:9

    Topics: Central Nervous System; Dimyristoylphosphatidylcholine; Lipid Bilayers; Molecular Dynamics Simulation; Piperazines; Quinazolines

2022